Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of patients

From: Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study

  All patients (N = 15)
Age, yr, median [IQR] 44 [36.5–63.5]
Female sex (%) 15 (100.0 %)
Disease duration, yr, median [IQR] 1 [0.5–6.5]
Whole unstimulated salivary flow (<0.1 ml/min) 12 (80 %)
Schirmer’s test ≤5 mm 10 (66.7 %)
Focus score ≥1 12 (80 %)
Baseline focus score, median [IQR] 1.6 [1–2.4]
Anti-SSA antibodies 14 (93.3 %)
Anti-SSB antibodies 10 (66.7 %)
Current background medication  
 Corticosteroids 4 (26.7 %)
 Hydroxychloroquine 5 (33.3 %)
 Methotrexate 0 (0 %)
Reason for inclusion  
 Systemic complications 11 (73.3 %)
 Recent-onset disease 4 (26.7 %)
 Increase in B-cell biomarker values 11 (73.3 %)
ESSDAI score (0–123), median [IQR] 7 [3–11]
ESSPRI score (0–10), median [IQR] 6.33 [6–7.33]
  1. Anti-SSA anti-Sjögren’s syndrome antigen A antibodies, anti-SSB anti-Sjögren’s syndrome antigen B antibodies, ESSDAI European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index, ESSPRI European League Against Rheumatism Sjögren’s Syndrome Patient Reported Index, IQR Interquartile range